FRANCE – Spartha Medical, a French medtech company specializing in the development of multifunctional antimicrobial, antiviral, and anti-inflammatory coatings, announced that it has received €2.4M (US$2.75M) in grants from the European Innovation Council (EIC) Fund, as well as an additional undisclosed equity financing.

Spartha Medical is one of 99 innovative European companies chosen by the EIC Accelerator program to receive a grant at the end of 2021. With a 6% selection rate in 2021, this is one of the most competitive European programs.

Spartha Medical’s innovative medical device coatings have antimicrobial, antiviral, and anti-inflammatory properties, including resistance to SARS-CoV-2 (Covid-19), making them highly versatile and practical for use in a wide range of surgical and patient care applications.

Spartha Medical’s innovation is also a one-of-a-kind non-antibiotic-based solution derived from natural biopolymers, making it biocompatible and applicable to all surface types.

Contact with the polymer-coated surfaces causes the antibacterial effect. With this key feature, the coating can be used on medical devices without interfering with their primary function, or it can act as a physical antibacterial/antiviral barrier, making it easier to enable use on implants for at-risk patients.

The medical coatings industry is expected to grow from US$6 billion (€5.2bn) in 2020 to US$15.2 billion (€13.3bn) by 2025, at a CAGR of 20.5%

In addition, the company provides a customized coating development service that tailors specific formulations to the needs of the client’s product.

Dr Nihal Engin Vrana, CEO of Spartha Medical said: “Spartha Medical is thrilled to have the support of the EIC fund, which we will use to launch clinical trials, strengthen our infrastructure and hire new talent.”

We are set to achieve the necessary regulatory compliance steps, including ISO certification, as well as start researching the next-generation of coatings. These will propel us to the forefront in preventing post-operative infections and in fighting against resistant bacteria,” he added.

The company is currently preparing a clinical trial to evaluate its antimicrobial medical coating kit, which will be used in surgeries and other patient care settings and will include dedicated instrumentation.

Spartha Medical is also developing a consumer product with antimicrobial and antiviral properties for use in personal and surface hygiene on a daily basis.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE